The demo reached each its Most important endpoints, with semaglutide 2.four mg demonstrating statistically substantial and exceptional improvements in liver fibrosis without having worsening of steatohepatitis, as well as resolution of steatohepatitis with no worsening of liver fibrosis in those with MASH as compared to placebo.oneThe developmental